Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24436902 | 0.77 | KDM4E (0.35) | — | |
| SCHEMBL27534228 | 0.74 | LMNA (0.33) | — | |
| SCHEMBL25166720 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL25166726 | 0.65 | — | — | |
| SCHEMBL1320483 | 0.65 | — | — | |
| SCHEMBL150170 | 0.58 | — | — | |
| SCHEMBL7525656 | 0.58 | CYP2D6 (0.41) | CYP2D6CYP2C19TP53 | |
| SCHEMBL28719441 | 0.58 | CYP2D6 (0.41) | CYP2D6CYP2C19TP53 | |
| SCHEMBL42490 | 0.58 | — | — | |
| Isobutane SCHEMBL6337855 | 0.57 | CA1 (0.56) | CYP2D6CYP2C19TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| EP-3898613-A1 | ANTICANCER COMPOUNDS | Pharma Mar S.A. (ES) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020127194-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056021-A1 | ANTICANCER COMPOUNDS | TP53, MCL1, MYC | CYP2D6 1373/4885CYP2C19 2602/4885TP53 1/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | CYP2D6 1371/4885CYP2C19 2600/4885TP53 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.